Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis

Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis

The primary objective of this study is to evaluate the efficacy of safety of etanercept dose reduction combined with sulfasalazine in ankylosing spondylitis (AS) patients who have achieved a significant clinical response.

Study Overview

• Status: Unknown
• Conditions: Ankylosing Spondylitis
• Intervention / Treatment: Drug: etanercept (Half-Dose); Drug: Sulfasalazine; Drug: Celecoxib; Drug: etanercept (Full-Dose)

Detailed Description

This single-centre, open-labeled randomized study will evaluate the efficacy of safety of etanercept dose reduction combined with sulfasalazine in patients who achieved a significant clinical response. AS patients who meet the inclusion criteria will take celecoxib (0.4g/d) during the whole period of study. In the first period, all patients will be given etanercept 50 mg subcutaneous injections weekly from baseline to week12. In the second period, patients who satisfied the criteria for disease remission will be randomized to one of the following three treatment arms: (1) Dose reduction arm: Patients will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. (2) Dose maintenance arm: Etanercept remains unchange from week12 to week24. (3) Etanercept discontinuation arm: Patients will be treated with sulfasalazine (2g/d) oral administration till week24. In the third period, all patients will take sulfasalazine (2g/d) till week 48. Ankylosing spondylitis disease activity score (ASDAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis metrology index (BASMI),Spondyloarthritis research consortium of Canada(SPARCC) score for the sacroiliac joint and adverse effect will be assessed in the study.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Phase 4

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients 18 to 45 years of age.
2. Proven AS according to the modified New York criteria
3. Negative result of a pregnancy test in serum in screening visit and in urine in baseline visit, done in all women, except those surgically sterilized and those who have at least one year of menopause.
4. Sexually active women of childbearing potential must agree and commit to use a medically accepted form of contraception.
5. ASDAS score ≥2.1
6. Ability to reconstitute the drug and self-inject it or have a person who can do so.
7. Capability to understand and voluntarily give written informed consent that is signed and dated, before any specific procedure of the protocol is performed.
8. Ability to store injectable test article at 2º to 8º C.

Exclusion Criteria:

1. Pregnancy/lactation.
2. Previously exposure to murine or chimeric monoclonal antibodies.
3. Receipt of any live (attenuated) vaccines within 4 weeks before screening visit.
4. History of chronic or a recent serious infection.
5. History of tuberculosis within the last 3 years.
6. History of malignancy.
7. Significant concurrent medical diseases including uncompensated congestive heart failure, myocardial infarction within 12 months, stable or unstable angina pectoris, uncontrolled hypertension, severe pulmonary disease, history of human immunodeficiency virus (HIV) infection, central nervous system demyelinating events suggestive of multiple sclerosis.
8. Presence or history of confirmed blood dyscrasias.
9. History of any viral hepatitis within 1 year prior screening or history of any drug-induced liver injury at any time prior to screening.
10. Laboratory exclusions are: hemoglobin level < 8.5 mg/dl white blood cell count < 3.5×10e9/l, platelet count < 125 ×10e9/l, creatinine level > 175 mcmol/l, liver enzymes > 1.5 times the upper limit of normal or alkaline phosphatase > 2 times the upper limit of normal.
11. Participation in trials of other investigational medications within 30 days of entering the study.
12. Clinical examination showing significant abnormalities of clinical relevance.
13. Concomitant medication with disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids.
14. Hypersensitivity to any regent of study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose reduction arm; AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.	Drug: etanercept (Half-Dose); AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .; Other Names: Enbrel; Drug: Sulfasalazine; AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will take sulfasalazine (2g/d) from week12 to week48.; Other Names: Sulazine; Drug: Celecoxib; Celecoxib (0.4g/d) will be the background therapy.; Other Names: Celebrex
Active Comparator: Dose maintenance arm; AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.	Drug: Sulfasalazine; AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will take sulfasalazine (2g/d) from week12 to week48.; Other Names: Sulazine; Drug: Celecoxib; Celecoxib (0.4g/d) will be the background therapy.; Other Names: Celebrex; Drug: etanercept (Full-Dose); AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.; Other Names: Enbrel
Other: Etanercept discontinuation arm; AS patients who achieved remission will take sulfasalazine (2g/d) till week24. Celecoxib will be the background therapy.	Drug: Sulfasalazine; AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will take sulfasalazine (2g/d) from week12 to week48.; Other Names: Sulazine; Drug: Celecoxib; Celecoxib (0.4g/d) will be the background therapy.; Other Names: Celebrex

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in ASDAS from baseline to week48.	ASDAS includes CRP (mg/L); Apart from the value of CRP, the four additional self-reported items (rated on 0-10 numerical rating scale [NRS]) included in this index are back pain, duration of morning stiffness, peripheral pain/swelling and patient global assessment of disease activity. The ASDAS scores are calculated as follows: ASDAS= (0.121×total back pain) + (0.110×subject global) + (0.073×peripheral pain/swelling) + (0.058×duration of morning stiffness) + (0.579×Ln(CRP+1)).	Baseline, Week12, Week24, Week48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in ESR from baseline to week48.	ESR is a laboratory test that provides a non-specific measure of inflammation. This test assesses the rate at which red blood cells fall in a test tube and is measured in mm/h. Normal range is 0 to 30 mm/h. A higher rate is consistent with inflammation.	Baseline, Week12, Week24, Week48
Change in CRP from baseline to week48.	CRP is a marker of inflammation and measured in mg/L. A higher level is consistent with inflammation.	Baseline, Week12, Week24, Week48
Change in BASFI from baseline to Week48.	BASFI is a validated self assessment tool that determines the degree of functional limitation in AS patients. Participants answered 10 questions, consisting of 8 specific questions regarding function in AS patients and 2 questions reflecting the participant's ability to cope with everyday life. Each question was answered on a 0-10 scale (0 being no problem and 10 being the worst problem), the sum of which (divided by 10) resulted in the BASFI score (0-10).	Baseline, Week12, Week24, Week48
Change in BASMI from baseline to Week48.	BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. Each measure was scored 0-2 (0=normal mobility, 2=severe reduction) to give a final score ranging 0 to 10.	Baseline, Week12, Week24, Week48
Change in SPARCC score for the sacroiliac joint from baseline to Week48.	SPARCC score for the sacroiliac joint was based on 6 consecutive coronal slices from posterior to anterior. Each joint was divided into 4 quadrants. Each quadrant was assigned a score of 0 = no lesion/1 = increased signal. For each slice, the score is increased by 1 for each joint that exhibits an intense signal in any quadrant. Also, for each slice, an additional score of 1 will be given for each joint that includes a lesion demonstrating continuous increased signal of a depth ≥1 cm from the articular surface. The maximum possible score is 72.	Baseline, Week12, Week24, Week48
Percentage of participants with serious adverse events (SAEs) or adverse events (AEs) by co-morbidity from baseline to Week48.	Any untoward medical occurrence in a participant who received study regents was considered an AE, without regard to possibility of relationship. An AE resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a SAE: death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.	Baseline, Week12, Week24, Week48

Collaborators and Investigators

• Sponsor: Zhixiang Huang
• Investigators: Principal Investigator: Tianwang Li, MD, Guangdong No.2 Provincial People's Hospital

Study record dates

Study Major Dates

• Study Start: January 1, 2016
• Primary Completion (Anticipated): February 1, 2017
• Study Completion (Anticipated): April 1, 2017

Study Registration Dates

• First Submitted: December 20, 2015
• First Submitted That Met QC Criteria: December 20, 2015
• First Posted (Estimate): December 23, 2015

Study Record Updates

• Last Update Posted (Estimate): December 28, 2015
• Last Update Submitted That Met QC Criteria: December 24, 2015
• Last Verified: December 1, 2015

More Information

Terms related to this study

• Keywords: Safety; Efficacy; dose; Ankylosing Spondylitis; Sulfasalazine; Etanercept; reduction
• Additional Relevant MeSH Terms: Infections; Joint Diseases; Musculoskeletal Diseases; Arthritis; Spinal Diseases; Bone Diseases; Spondylarthropathies; Bone Diseases, Infectious; Ankylosis; Spondylitis; Spondylarthritis; Spondylitis, Ankylosing; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Immunosuppressive Agents; Immunologic Factors; Gastrointestinal Agents; Cyclooxygenase 2 Inhibitors; Etanercept; Celecoxib; Sulfasalazine
• Other Study ID Numbers: 2015117183344589

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No